Duchenne muscular dystrophy gene therapy in the canine model

Human Gene Therapy Clinical Development

Volumn 26, Issue 1, 2015, Pages 57-69

  Duan, Dongsheng ^a  

^a University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; DYSTROPHIN; MYOSTATIN; PARVOVIRUS VECTOR; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; UTROPHIN;

ARTICLE; CANINE MODEL; CELLULAR IMMUNITY; DUCHENNE MUSCULAR DYSTROPHY; EXON SKIPPING; GENE MUTATION; GENE THERAPY; GENE VECTOR; HUMAN; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM; X CHROMOSOME LINKED DISORDER; ANIMAL; DEPENDOPARVOVIRUS; DISEASE MODEL; DOG; GENETICS; IMMUNOLOGY; MUSCULAR DYSTROPHY, ANIMAL; MUSCULAR DYSTROPHY, DUCHENNE; T LYMPHOCYTE;

CANIS FAMILIARIS; MUS;

ANIMALS; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; DOGS; GENETIC THERAPY; HUMANS; MUSCULAR DYSTROPHY, ANIMAL; MUSCULAR DYSTROPHY, DUCHENNE; T-LYMPHOCYTES;

EID: 84965083473     PISSN: 23248637     EISSN: 23248645     Source Type: Journal    
DOI: 10.1089/humc.2015.006     Document Type: Article

References (150)

1. Hoffman EP, Brown RH Jr., Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987;51:919-928.
2. Koenig M, Hoffman EP, Bertelson CJ, et al. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 1987;50: 509-517.
3. Mendell JR, Lloyd-Puryear M. Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy. Muscle Nerve 2013;48:21-26.
4. Emery AEH, Muntoni F. Duchenne Muscular Dystrophy, 3rd ed. (Oxford University Press, New York, NY). 2003.
5. Kinnett K, Cripe LH. Transforming Duchenne care: meeting 25-26 June 2012, Ft. Lauderdale, Florida, USA. Neuromuscul Disord 2013;23:690-695.
6. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 2010;9:177-189.
7. Rodino-Klapac LR, Chicoine LG, Kaspar BK, Mendell JR. Gene therapy for Duchenne muscular dystrophy: expectations and challenges. Arch Neurol 2007;64: 1236-1241.
8. McGreevy JW, Hakim CH, McIntosh MA, Duan D. Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy. Dis Model Mech 2015. [Epub ahead of print]
9. Duan D. Duchenne muscular dystrophy gene therapy: lost in translation? Res Rep Biol 2011;2:31-42.
10. Foster H, Popplewell L, Dickson G. Genetic therapeutic approaches for Duchenne muscular dystrophy. Hum Gene Ther 2012;23:676-687.
11. Chamberlain JS. Gene therapy of muscular dystrophy. Hum Mol Genet 2002;11:2355-2362.
12. Banks GB, Chamberlain JS. The value of mammalian models for Duchenne muscular dystrophy in developing therapeutic strategies. Curr Top Dev Biol 2008;84: 431-453.
13. Sicinski P, Geng Y, Ryder-Cook AS, et al. The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 1989;244:1578-1580.
14. BulfieldG,SillerWG,Wight PA,Moore KJ.Xchromosomelinked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci USA 1984;81:1189-1192.
15. Cooper BJ, Winand NJ, Stedman H, et al. The homologue of the Duchenne locus is defective in X-linked muscular dystrophy of dogs. Nature 1988;334:154-156.
16. Valentine BA, Cooper BJ, Cummings JF, deLahunta A. Progressive muscular dystrophy in a golden retriever dog: light microscope and ultrastructural features at 4 and 8 months. Acta Neuropathol (Berl) 1986;71:301-310.
17. Shimatsu Y, Yoshimura M, Yuasa K, et al. Major clinical and histopathological characteristics of canine X-linked muscular dystrophy in Japan, CXMDJ. Acta Myol 2005;24:145-154.
18. Valentine BA, Cooper BJ, de Lahunta A, et al. Canine Xlinked muscular dystrophy-an animal model of Duchenne muscular dystrophy: clinical studies. J Neurol Sci 1988; 88:69-81.
19. Walmsley GL, Arechavala-Gomeza V, Fernandez-Fuente M, et al. A Duchenne muscular dystrophy gene hot spot mutation in dystrophin-deficient cavalier king charles spaniels is amenable to exon 51 skipping. PLoS One 2010;5:e8647.
20. Schatzberg SJ, Olby NJ, Breen M, et al. Molecular analysis of a spontaneous dystrophin 'knockout' dog. Neuromuscul Disord 1999;9:289-295.
21. Kornegay JN, Tuler SM, Miller DM, Levesque DC. Muscular dystrophy in a litter of golden retriever dogs. Muscle Nerve 1988;11:1056-1064.
22. Klarenbeek S, Gerritzen-Bruning MJ, Rozemuller AJ, van der Lugt JJ. Canine X-linked muscular dystrophy in a family of Grand Basset Griffon Vendeen dogs. J Comp Pathol 2007;137:249-252.
23. Jones BR, Brennan S, Mooney CT, et al. Muscular dystrophy with truncated dystrophin in a family of Japanese Spitz dogs. J Neurol Sci 2004;217:143-149.
24. Bergman RL, Inzana KD, Monroe WE, et al. Dystrophindeficient muscular dystrophy in a Labrador retriever. J Am Anim Hosp Assoc 2002;38:255-261.
25. Paola JP, Podell M, Shelton GD. Muscular dystrophy in a miniature Schnauzer. Prog Vet Neurol 1993;4:14-18.
26. Wieczorek LA, Garosi LS, Shelton GD. Dystrophindeficient muscular dystrophy in an old English sheepdog. Vet Rec 2006;158:270-273.
27. Wetterman CA, Harkin KR, Cash WC, et al. Hypertorphic muscular dystrophy in a young dog. J Am Vet Med Assoc 2000;216:878-881.
28. Baltzer WI, Calise DV, Levine JM, et al. Dystrophindeficient muscular dystrophy in a Weimaraner. J Am Anim Hosp Assoc 2007;43:227-232.
29. Baroncelli AB, Abellonio F, Pagano TB, et al. Muscular dystrophy in a dog resembling human Becker muscular dystrophy. J Comp Pathol 2014;150:429-433.
30. Ito D, Kitagawa M, Jeffery N, et al. Dystrophin-deficient muscular dystrophy in an Alaskan malamute. Vet Rec 2011;169:127.
31. Smith BF, Yue Y, Woods PR, et al. An intronic LINE-1 element insertion in the dystrophin gene aborts dystrophin expression and results in Duchenne-like muscular dystrophy in the corgi breed. Lab Invest 2011;91:216-231.
32. Smith BF, Kornegay JN, Duan D. Independent canine models of Duchenne muscular dystrophy due to intronic insertions of repetitive DNA. Mol Ther 2007;15:S51.
33. Beltran E, Shelton GD, Guo LT, et al. Dystrophindeficient muscular dystrophy in a Norfolk terrier. J Small Anim Pract 2014. [Epub ahead of print]; doi:10.1111/ jsap.12292.
34. Kornegay JN, Bogan JR, Bogan DJ, et al. Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies. Mam Genome 2012;23:85-108.
35. Fine DM, Shin JH, Yue Y, et al. Age-matched comparison reveals early electrocardiography and echocardiography changes in dystrophin-deficient dogs. Neuromuscul Disord 2011;21:453-461.
36. Shin JH, Yue Y, Smith B, Duan D. Humoral immunity to AAV-6, 8, and 9 in normal and dystrophic dogs. Hum Gene Ther 2012;23:287-294.
37. Shin JH, Yue Y, Srivastava A, et al. A simplified immune suppression scheme leads to persistent micro-dystrophin expression in Duchenne muscular dystrophy dogs. Hum Gene Ther 2012;23:202-209.
38. Yang HT, Shin JH, Hakim CH, et al. Dystrophin deficiency compromises force production of the extensor carpi ulnaris muscle in the canine model of Duchenne muscular dystrophy. PLoS One 2012;7:e44438.
39. Shin JH, Greer B, Hakim CH, et al. Quantitative phenotyping of Duchenne muscular dystrophy dogs by comprehensive gait analysis and overnight activity monitoring. PLoS One 2013;8:e59875.
40. Shin JH, Pan X, Hakim CH, et al. Microdystrophin ameliorates muscular dystrophy in the canine model of Duchenne muscular dystrophy. Mol Ther 2013;21:750-757.
41. Basner-Tschakarjan E, Mingozzi F. Cell-mediated immunity to AAV vectors, evolving concepts and potential solutions. Front Immunol 2014;5:350.
42. Mendell JR, Rodino-Klapac L, Sahenk Z, et al. Gene therapy for muscular dystrophy: lessons learned and path forward. Neurosci Lett 2012;527:90-99.
43. Mendell JR, Campbell K, Rodino-Klapac L, et al. Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med 2010;363:1429-1437.
44. Wang Z, Allen JM, Riddell SR, et al. Immunity to adenoassociated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy. Hum Gene Ther 2007;18:18-26.
45. Yuasa K, Yoshimura M, Urasawa N, et al. Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products. Gene Ther 2007;14:1249-1260.
46. Yue Y, Ghosh A, Long C, et al. A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs. Mol Ther 2008;16:1944-1952.
47. Wright JF. Manufacturing and characterizing AAV-based vectors for use in clinical studies. Gene Ther 2008;15: 840-848.
48. Wilson JM. Progress in the commercial-scale production of adeno-associated viral vectors. Hum Gene Ther 2009; 20:695.
49. Kunkel LM. 2004 William Allan award address. cloning of the DMD gene. Am J Hum Genet 2005;76:205-214.
50. Howell JM, Fletcher S, O'Hara A, et al. Direct dystrophin and reporter gene transfer into dog muscle in vivo. Muscle Nerve 1998;21:159-165.
51. Thioudellet C, Blot S, Squiban P, et al. Current protocol of a research phase I clinical trial of full-length dystrophin plasmid DNA in Duchenne/Becker muscular dystrophies. Part I: rationale. Neuromuscul Disord 2002;12:S49-S51.
52. Duan D. Myodys, a full-length dystrophin plasmid vector for Duchenne and Becker muscular dystrophy gene therapy. Curr Opin Mol Ther 2008;10:86-94.
53. Pichavant C, Chapdelaine P, Cerri DG, Bizario JC, Tremblay JP. Electrotransfer of the full-length dog dystrophin into mouse and dystrophic dog muscles. Hum Gene Ther 2010;21:1591-1601.
54. Pichavant C, Chapdelaine P, Cerri DG, et al. Expression of dog microdystrophin in mouse and dog muscles by gene therapy. Mol Ther 2010;18:1002-1009.
55. Danthinne X, Imperiale MJ. Production of first generation adenovirus vectors: a review. Gene Ther 2000;7:1707-1714.
56. Ragot T, Vincent N, Chafey P, et al. Efficient adeno-virus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice. Nature 1993;361: 647-650.
57. England SB, Nicholson LV, Johnson MA, et al. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 1990;343:180-182.
58. Howell JM, Lochmuller H, O'Hara A, et al. High-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscle of dystrophic dogs: prolongation of expression with immunosuppression. Hum Gene Ther 1998;9:629-634.
59. O'Hara AJ, Howell JM, Taplin RH, et al. The spread of transgene expression at the site of gene construct injection. Muscle Nerve 2001;24:488-495.
60. Parks RJ, Graham FL. A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging. J Virol 1997;71:3293-3298.
61. Gilbert R, Nalbantoglu J, Howell JM, et al. Dystrophin expression in muscle following gene transfer with a fully deleted (''gutted'') adenovirus is markedly improved by trans-acting adenoviral gene products. Hum Gene Ther 2001;12:1741-1755.
62. Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 2011;12:341-355.
63. Lai Y, Yue Y, Duan D. Evidence for the failure of adenoassociated virus serotype 5 to package a viral genome > or = 8.2 kb. Mol Ther 2010;18:75-79.
64. Scott J, Li S, Harper S, et al. Viral vectors for gene transfer of micro-, mini-, or full-length dystrophin. Neuromuscul Disord 2002;12:S23.
65. Dickson G, Roberts M, Wells D, Fabb S. Recombinant micro-genes and dystrophin viral vectors. Neuromuscul Disord 2002;12:S40.
66. Arikawa-Hirasawa E, Koga R, Tsukahara T, et al. A severe muscular dystrophy patient with an internally deleted very short (110 kD) dystrophin: presence of the binding site for dystrophin-associated glycoprotein (DAG) may not be enough for physiological function of dystrophin. Neuromuscul Disord 1995;5:429-438.
67. Den Dunnen JT, Grootscholten PM, Bakker E, et al. Topography of the Duchenne muscular dystrophy (DMD) gene: FIGE and cDNA analysis of 194 cases reveals 115 deletions and 13 duplications. Am J Hum Genet 1989; 45:835-847.
68. Fanin M, Freda MP, Vitiello L, et al. Duchenne phenotype with in-frame deletion removing major portion of dystrophin rod: threshold effect for deletion size? Muscle Nerve 1996;19:1154-1160.
69. Koenig M, Beggs AH, Moyer M, et al. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet 1989;45:498-506.
70. Yue Y, Li Z,Harper SQ, et al.Microdystrophin gene therapy of cardiomyopathy restores dystrophin-glycoprotein complex and improves sarcolemma integrity in the mdx mouse heart. Circulation 2003;108:1626-1632.
71. Gregorevic P, Allen JM, Minami E, et al. rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat Med 2006;12: 787-789.
72. Gregorevic P, Blankinship MJ, Allen JM, et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med 2004;10:828-834.
73. Lai Y, Thomas GD, Yue Y, et al. Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J Clin Invest 2009;119: 624-635.
74. Gregorevic P, Blankinship MJ, Allen JM, Chamberlain JS. Systemic microdystrophin gene delivery improves skeletal muscle structure and function in old dystrophic mdx mice. Mol Ther 2008;16:657-664.
75. Bostick B, Yue Y, Lai Y, et al. Adeno-associated virus serotype-9 microdystrophin gene therapy ameliorates electrocardiographic abnormalities in mdx mice. Hum Gene Ther 2008;19:851-856.
76. Bostick B, Shin J-H, Yue Y, Duan D.AAV-microdystrophin therapy improves cardiac performance in aged female mdx mice. Mol Ther 2011;19:1826-1832.
77. Liu M, Yue Y, Harper SQ, et al. Adeno-associated virusmediated microdystrophin expression protects young mdx muscle from contraction-induced injury. Mol Ther 2005; 11:245-256.
78. Yue Y, Liu M, Duan D. C-terminal truncated microdystrophin recruits dystrobrevin and syntrophin to the dystrophin-associated glycoprotein complex and reduces muscular dystrophy in symptomatic utrophin/dystrophin double knock-out mice. Mol Ther 2006;14:79-87.
79. Yoshimura M, Sakamoto M, Ikemoto M, et al. AAV vector-mediated microdystrophin expression in a relatively small percentage of mdx myofibers improved the mdx phenotype. Mol Ther 2004;10:821-828.
80. Fabb SA, Wells DJ, Serpente P, Dickson G. Adenoassociated virus vector gene transfer and sarcolemmal expression of a 144 kDa micro-dystrophin effectively restores the dystrophin-associated protein complex and inhibits myofibre degeneration in nude/mdx mice. Hum Mol Genet 2002;11:733-741.
81. Wang B, Li J, Xiao X. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc Natl Acad Sci USA 2000;97:13714-13719.
82. Harper SQ, Hauser MA, DelloRusso C, et al. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat Med 2002;8:253-261.
83. Sampaolesi M, Blot S, D'Antona G, et al. Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature 2006;444:574-579.
84. Kornegay JN, Li J, Bogan JR, et al. Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs. Mol Ther 2010;18:1501-1508.
85. Banks GB, Judge LM, Allen JM, Chamberlain JS. The polyproline site in hinge 2 influences the functional capacity of truncated dystrophins. PLoS Genet 2010;6: e1000958.
86. Lai Y, Zhao J, Yue Y, Duan D. alpha2 and alpha3 helices of dystrophin R16 and R17 frame a microdomain in the alpha1 helix of dystrophin R17 for neuronal NOS binding. Proc Natl Acad Sci USA 2013;110:525-530.
87. Foster H, Sharp PS, Athanasopoulos T, et al. Codon and mRNA sequence optimization of microdystrophin trans-genes improves expression and physiological outcome in dystrophic mdx mice following AAV2/8 gene transfer. Mol Ther 2008;16:1825-1832.
88. Li D, Yue Y, Lai Y, et al. Nitrosative stress elicited by nNOSmu delocalization inhibits muscle force in dystro-phin-null mice. J Pathol 2011;223:88-98.
89. Monaco AP, Bertelson CJ, Liechti-Gallati S, et al. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 1988;2:90-95.
90. Beggs AH, Hoffman EP, Snyder JR, et al. Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. Am J Hum Genet 1991;49:54-67.
91. McClorey G, Moulton HM, Iversen PL, et al. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Ther 2006;13:1373-1381.
92. Yokota T, Lu QL, Partridge T, et al. Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol 2009;65:667-676.
93. Fletcher S, Ly T, Duff RM, et al. Cryptic splicing involving the splice site mutation in the canine model of Duchenne muscular dystrophy. Neuromuscul Disord 2001;11:239-243.
94. Douglas AG, Wood MJ. Splicing therapy for neuromuscular disease. Mol Cell Neurosci 2013;56:169-185.
95. Yokota T, Nakamura A, Nagata T, et al. Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs. Nucleic Acid Ther 2012;22:306-315.
96. Goyenvalle A, Vulin A, Fougerousse F, et al. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science 2004;306:1796-1799.
97. Gorman L, Suter D, Emerick V, et al. Stable alteration of pre-mRNA splicing patterns by modified U7 small nuclear RNAs. Proc Natl Acad Sci USA 1998;95:4929-4934.
98. Suter D, Tomasini R, Reber U, et al. Double-target antisense U7 snRNAs promote efficient skipping of an aberrant exon in three human beta-thalassemic mutations. Hum Mol Genet 1999;8:2415-2423.
99. Vulin A, Barthelemy I, Goyenvalle A, et al. Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping. Mol Ther 2012;20:2120-2133.
100. Le Guiner C, Montus M, Servais L, et al. Forelimb treatment in a large cohort of dystrophic dogs supports delivery of a recombinant AAV for exon skipping in Duchenne patients. Mol Ther 2014;22:1923-1935.
101. Barbash IM, Cecchini S, Faranesh AZ, et al. MRI roadmap-guided transendocardial delivery of exonskipping recombinant adeno-associated virus restores dystrophin expression in a canine model of Duchenne muscular dystrophy. Gene Ther 2013;20:274-282.
102. Bish LT, Sleeper MM, Forbes SC, et al. Long-term restoration of cardiac dystrophin expression in golden retriever muscular dystrophy following rAAV6-mediated exon skipping. Mol Ther 2012;20:580-589.
103. Bartlett RJ, Stockinger S, Denis MM, et al. In vivo targeted repair of a point mutation in the canine dystrophin gene by a chimeric RNA/DNA oligonucleotide. Nat Biotechnol 2000;18:615-622.
104. Swaggart KA, McNally EM. Modifiers of heart and muscle function: where genetics meets physiology. Exp Physiol 2014;99:621-626.
105. Cerletti M, Negri T, Cozzi F, et al. Dystrophic phenotype of canine X-linked muscular dystrophy is mitigated by adenovirus-mediated utrophin gene transfer. Gene Ther 2003;10:750-757.
106. Odom GL, Gregorevic P, Allen JM, et al. Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin/utrophindeficient mice. Mol Ther 2008;16:1539-1545.
107. Lee SJ. Regulation of muscle mass by myostatin. Annu Rev Cell Dev Biol 2004;20:61-86.
108. Bogdanovich S, Krag TO, Barton ER, et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature 2002;420:418-421.
109. Mosher DS, Quignon P, Bustamante CD, et al. A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs. PLoS Genet 2007;3:e79.
110. Bish LT, Sleeper MM, Forbes SC, et al. Long-term systemic myostatin inhibition via liver-targeted gene transfer in golden retriever muscular dystrophy. Hum Gene Ther 2011;22:1499-1509.
111. Cotten SW, Kornegay JN, Bogan DJ, et al. Genetic myostatin decrease in the golden retriever muscular dystrophy model does not significantly affect the ubiquitin proteasome system despite enhancing the severity of disease. Am J Transl Res 2014;6:43-53.
112. Shin JH, Bostick B, Yue Y, et al. SERCA2a gene transfer improves electrocardiographic performance in aged mdx mice. J Transl Med 2011;9:132.
113. Ferretti R, Marques MJ, Pertille A, Santo Neto H. Sarcoplasmic-endoplasmic-reticulum Ca2 + -ATPase and calsequestrin are overexpressed in spared intrinsic laryngeal muscles of dystrophin-deficient mdx mice. Muscle Nerve 2009;39:609-615.
114. Goonasekera SA, Lam CK, Millay DP, et al. Mitigation of muscular dystrophy in mice by SERCA overexpression in skeletal muscle. J Clin Invest 2011;121:1044-1052.
115. Morine KJ, Sleeper MM, Barton ER, Sweeney HL. Overexpression of SERCA1a in the mdx diaphragm reduces susceptibility to contraction-induced damage. Hum Gene Ther 2010;21:1735-1739.
116. Bouyon S,RousselV,FromesY.SERCA2a gene therapy can improve symptomatic heart failure in delta-sarcoglycandeficient animals. Hum Gene Ther 2014;25:694-704.
117. Zhu X, McTiernan CF, Rajagopalan N, et al. Immunosuppression decreases inflammation and increases AAV6-hSERCA2a-mediated SERCA2a expression. Hum Gene Ther 2012;23:722-732.
118. Mi YF, Li XY, Tang LJ, et al. Improvement in cardiac function after sarcoplasmic reticulum Ca2 + -ATPase gene transfer in a beagle heart failure model. Chin Med J 2009;122:1423-1428.
119. Wang Z, Zhu T, Qiao C, et al. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol 2005;23:321-328.
120. Bostick B, Ghosh A, Yue Y, et al. Systemic AAV-9 transduction in mice is influenced by animal age but not by the route of administration. Gene Ther 2007;14:1605-1609.
121. Pacak CA, Mah CS, Thattaliyath BD, et al. Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ Res 2006;99:e3-9.
122. Pan X, Yue Y, Zhang K, et al. Long-term robust myocardial transduction of the dog heart from a peripheral vein by adeno-associated virus serotype-8. Hum Gene Ther 2013;24:584-594.
123. Hakim CH, Yue Y, Shin JH, et al. Systemic gene transfer reveals distinctive muscle transduction profile of tyrosine mutant AAV-1, - 6, and - 9 in neonatal dogs. Mol Ther Methods Clin Dev 2014;1:14002.
124. Wang Z, Kuhr CS, Allen JM, et al. Sustained AAVmediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol Ther 2007;15:1160-1166.
125. Rapti K, Louis-Jeune V, Kohlbrenner E, et al. Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models. Mol Ther 2011;20:73-83.
126. Denard J, Beley C, Kotin R, et al. Human galectin 3 binding protein interacts with recombinant adeno-associated virus type 6. J Virol 2012;86:6620-6631.
127. Yue Y, Pan X, Hakim CH, et al. Safe and bodywide muscle gene transfer in young adult Duchenne muscular dystrophy dogs. New Directions in Biology and Disease of Skeletal Muscle, 2014, Chicago, Illinois, June 29-July 22, 2014.
128. Wang Z, Storb R, Lee D, et al. Immune responses to AAV in canine muscle monitored by cellular assays and noninvasive imaging. Mol Ther 2010;18:617-624.
129. Wang Z, Halbert CL, Lee D, et al. Elimination of contaminating cap genes in AAV vector virions reduces immune responses and improves transgene expression in a canine gene therapy model. Gene Ther 2014;21:363-370.
130. Bish LT, Sleeper MM, Brainard B, et al. Percutaneous transendocardial delivery of self-complementary adenoassociated virus 6 achieves global cardiac gene transfer in canines. Mol Ther 2008;16:1953-1959.
131. Ohshima S, Shin JH, Yuasa K, et al. Transduction efficiency and immune response associated with the administration of AAV8 vector into dog skeletal muscle. Mol Ther 2009;17:73-80.
132. Qiao C, Li J, Zheng H, et al. Hydrodynamic limb vein injection of AAV8 canine myostatin propeptide gene in normal dogs enhances muscle growth. Hum Gene Ther 2009;20:1-10.
133. Koo T, Okada T, Athanasopoulos T, et al. Long-term functional adeno-associated virus-microdystrophin expression in the dystrophic CXMDj dog. J Gene Med 2011;13:497-506.
134. Childers MK, Joubert R, Poulard K, et al. Gene therapy prolongs survival and restores function in murine and canine models of myotubular myopathy. Sci Transl Med 2014;6:220ra210.
135. Vandenberghe LH, Wang L, Somanathan S, et al. Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid. Nat Med 2006;12:967-971.
136. Lu Y, Song S. Distinct immune responses to transgene products from rAAV1 and rAAV8 vectors. Proc Natl Acad Sci USA 2009;106:17158-17162.
137. Wang L, Figueredo J, Calcedo R, et al. Cross-presentation of adeno-associated virus serotype 2 capsids activates cytotoxic T cells but does not render hepatocytes effective cytolytic targets. Hum Gene Ther 2007;18:185-194.
138. Xin KQ, Mizukami H, Urabe M, et al. Induction of robust immune responses against human immunodeficiency virus is supported by the inherent tropism of adeno-associated virus type 5 for dendritic cells. J Virol 2006;80:11899-11910.
139. Mays LE,Vandenberghe LH, Xiao R, et al.Adeno-associated virus capsid structure drives CD4-dependent CD8 + T cell response to vector encoded proteins. J Immunol 2009;182: 6051-6060.
140. Faust SM, Bell P, Cutler BJ, et al. CpG-depleted adenoassociated virus vectors evade immune detection. J Clin Invest 2013;123:2994-3001.
141. Rozkalne A, Adkin C, Meng J, et al. Mouse regenerating myofibers detected as false-positive donor myofibers with anti-human spectrin. Hum Gene Ther 2014;25:73-81.
142. Kodippili K, Vince L, Shin JH, et al. Characterization of 65 epitope-specific dystrophin monoclonal antibodies in canine and murine models of Duchenne muscular dystrophy by immunostaining and western blot. PLoS One 2014;9:e88280.
143. Wells DJ, Wells KE, Asante EA, et al. Expression of human full-length and minidystrophin in transgenic mdx mice: implications for gene therapy of Duchenne muscular dystrophy. Hum Mol Genet 1995;4:1245-1250.
144. Phelps SF, Hauser MA, Cole NM, et al. Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. Hum Mol Genet 1995;4:1251-1258.
145. Odom GL, Gregorevic P, Allen JM, Chamberlain JS. Gene therapy of mdx mice with large truncated dystrophins generated by recombination using rAAV6. Mol Ther 2011;19:36-45.
146. Zhang Y, Duan D. Novel mini-dystrophin gene dual adeno-associated virus vectors restore neuronal nitric oxide synthase expression at the sarcolemma. Hum Gene Ther 2012;23:98-103.
147. Zhang Y, Yue Y, Li L, et al. Dual AAV therapy ameliorates exercise-induced muscle injury and functional ischemia in murine models of Duchenne muscular dystrophy. Hum Mol Genet 2013;22:3720-3729.
148. Ousterout DG, Kabadi AM, Thakore PI, et al. Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases. Mol Ther 2014. [Epub ahead of print]; doi: 10.1038/mt.2014.234.
149. Ousterout DG, Perez-Pinera P, Thakore PI, et al. Reading frame correction by targeted genome editing restores dystrophin expression in cells from Duchenne muscular dystrophy patients. Mol Ther 2013;21:1718-1726.
150. Long C, McAnally JR, Shelton JM, et al. Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA. Science 2014;345:1184-1188.